CRITICAL PATH INSTITUTE: Form 990, tax year 2019
View the entire original 990 at ProPublica ↗
- Organization
- CRITICAL PATH INSTITUTE (EIN 20-1991334)
- Tax period
- 2019-07-01 to 2020-06-30
- Filed
- 2021-05-07
- IRS object ID
- 202111279349303111
- Schema version
- 2019v5.2
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule L
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2021-05-07T17:24:26-05:00 | ReturnTs |
| Tax Period End | 2020-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 860683059 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEACHFLEISCHMAN PC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1985 E RIVER ROAD SUITE 201 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 85718 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2019-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 201991334 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | CRIT | BusinessNameControlTxt |
| Phone | 5205473440 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | KRISTEN L SWINGLE | PersonNm |
| Person Title | COO | PersonTitleTxt |
| Phone | 5205473440 | PhoneNum |
| Signature | 2021-05-07 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KELLY L MELTZER CPA | PreparerPersonNm |
| PTIN | P00633511 | PTIN |
| Phone | 5203214600 | PhoneNum |
| Preparation | 2021-05-07 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2019 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | KRISTEN L SWINGLE | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $18,464,314 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.C-PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2004 | FormationYr |
| Legal Domicile State | AZ | LegalDomicileStateCd |
| Activity Or Mission | CREATE AND MANAGE INTERNATIONAL COLLABORATIONS AND DEVELOP NOVEL TOOLS, ENABLING THE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 13 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 12 | VotingMembersIndependentCnt |
| Total Employee | 99 | TotalEmployeeCnt |
| Total Volunteers | 12 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $10,698,823 | PYContributionsGrantsAmt |
| CY Contributions Grants | $12,978,641 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $5,883,801 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $5,292,779 | CYProgramServiceRevenueAmt |
| PY Investment Income | $215,046 | PYInvestmentIncomeAmt |
| CY Investment Income | $156,753 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $36,141 | CYOtherRevenueAmt |
| PY Total Revenue | $16,797,670 | PYTotalRevenueAmt |
| CY Total Revenue | $18,464,314 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $2,107,859 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,697,926 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $8,456,998 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $10,893,350 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $4,808,109 | PYOtherExpensesAmt |
| CY Other Expenses | $3,961,324 | CYOtherExpensesAmt |
| PY Total Expenses | $15,372,966 | PYTotalExpensesAmt |
| CY Total Expenses | $17,552,600 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $1,424,704 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $911,714 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $17,507,463 | TotalAssetsBOYAmt |
| Total Assets EOY | $16,657,850 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $9,360,374 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $7,630,738 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $8,147,089 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $9,027,112 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $13,428,896 | ExpenseAmt |
| Grant | $2,697,926 | GrantAmt |
| Revenue | $5,328,920 | RevenueAmt |
| Desc | SEE SCHEDULE O | Desc |
| Total Program Service Expenses | $13,428,896 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | Yes (1) | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 25 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 99 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | EI | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 13 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 12 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANNA M MIDKIFF CPA | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 5206478382 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (30 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Former Ofcr Director TrusteeFormerOfcrDirectorTrusteeInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DR MARTHA A BRUMFIELD | |||||||||
| FORMER PRESIDENT & CEO | 20.00 | Yes (X) | $236,390 | $0 | $24,051 | ||||
| DR JOSEPH SCHEEREN | |||||||||
| PRESIDENT & CHIEF EXECUTIVE OFFICER | 40.00 | $242,633 | $0 | $17,100 | Yes (X) | Yes (X) | |||
| DR LYNN HUDSON | |||||||||
| CHIEF SCIENCE OFFICER | 40.00 | $210,012 | $0 | $17,691 | Yes (X) | ||||
| DR JOHN MICHEL SAUER | |||||||||
| PROGRAM OFFICER | 40.00 | $195,991 | $0 | $31,601 | Yes (X) | ||||
| DR STEPHEN COONS | |||||||||
| PROGRAM OFFICER | 40.00 | $187,345 | $0 | $26,911 | Yes (X) | ||||
| DR DIANE STEPHENSON | |||||||||
| EXECUTIVE DIRECTOR | 40.00 | $175,666 | $0 | $25,784 | Yes (X) | ||||
| DR KLAUS ROMERO | |||||||||
| CHIEF SCIENCE OFFICER | 40.00 | $182,952 | $0 | $17,154 | Yes (X) | ||||
| DR INISH O'DOHERTY | |||||||||
| EXECUTIVE DIRECTOR | 40.00 | $181,018 | $0 | $16,206 | Yes (X) | ||||
| MS SONYA EREMENCO | |||||||||
| ASSOCIATE DIRECTOR | 40.00 | $160,608 | $0 | $24,670 | Yes (X) | ||||
| DR RICHARD LIWSKI | |||||||||
| CHIEF TECHNOLOGY OFFICER | 40.00 | $163,994 | $0 | $17,984 | Yes (X) | ||||
| DR ARIANA MULLIN | |||||||||
| EXECUTIVE DIRECTOR | 40.00 | $154,963 | $0 | $19,122 | Yes (X) | ||||
| DR MARCO SHITO | |||||||||
| SCIENTIFIC DIRECTOR | 40.00 | $138,031 | $0 | $21,660 | Yes (X) | ||||
| MR STEVEN BROADBENT | |||||||||
| FORMER COO & TREASURER | 40.00 | Yes (X) | $123,553 | $0 | $18,079 | ||||
| MR LEWIS BARBIERI | |||||||||
| CORPORATE SECRETARY | 40.00 | $120,637 | $0 | $19,858 | Yes (X) | ||||
| MS KRISTEN SWINGLE | |||||||||
| CHIEF OPERATING OFFICER & TREASURER | 40.00 | $126,647 | $0 | $12,040 | Yes (X) | ||||
| DR D CRAIG BRATER | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MS KAY HOLCOMBE | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR PETER BARTON HUTT | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR JEFFREY JACOB | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR SHAUN A KIRKPATRICK | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR ALAN G LEVIN | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| DR ALASTAIR JJ WOOD | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR JAMES W NEWMAN | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| DR PAULA J OLSIEWSKI | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| DR TOMAS SALMONSON | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MS CINDY PARSEGHIAN | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| MR RICHARD T MYERS JR | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| DR MICHAEL KASSER | |||||||||
| BOARD MEMBER | 1.00 | $0 | $0 | $0 | Yes (X) | ||||
| DR TIMOTHY R FRANSON | |||||||||
| CHAIR | 1.00 | $0 | $0 | $0 | Yes (X) | Yes (X) | |||
| MR M WAINWRIGHT FISHBURN JR | |||||||||
| VICE-CHAIR | 1.00 | $0 | $0 | $0 | Yes (X) | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,600,440 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $309,911 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 22 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | Yes (1) | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| EPHIBIAN INC | |||||
| 3180 N SWAN RD | TUCSON | AZ | 85712 | PLATFORM SERVICES | $160,376 |
| LOTOS NILE | |||||
| PO BOX 90245 | NASHVILLE | TN | 37209 | PUBLIC RELATIONS | $159,274 |
| EDETEK INC | |||||
| 101 COLLEGE RD W EAST 2ND FLOOR | PRINCETON | NJ | 08540 | SUBAWARD | $157,500 |
| AMY C PORTER | |||||
| 4201 N QUAIL CANYON DR | TUCSON | AZ | 85750 | CONSULTING | $156,600 |
| RTI HEALTH SOLUTIONS | |||||
| 200 PARK OFFICERS DRIVE | RESEARCH TRIANGLE PARK | NC | 27709 | T&M | $143,685 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 5 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $7,179,419 | GovernmentGrantsAmt |
| All Other Contributions | $5,799,222 | AllOtherContributionsAmt |
| Total Contributions | $12,978,641 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| RESEARCH SUPPORT FEES | 541700 | $5,253,708 | $5,253,708 |
| OTHER REVENUE | 900099 | $39,071 | $39,071 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $5,292,779 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $156,753 | TotalRevenueColumnAmt |
| Exclusion | $156,753 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | EARNINGS FROM SUBSIDIARY | Desc |
| Business | 900099 | BusinessCd |
| Total Revenue Column | $36,141 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $36,141 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $36,141 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $18,464,314 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $5,328,920 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $156,753 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,499,467 | TotalAmt |
| Program Services | $2,499,467 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $198,459 | TotalAmt |
| Program Services | $198,459 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,966,157 | TotalAmt |
| Program Services | $1,471,956 | ProgramServicesAmt |
| Management And General | $494,201 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,088,060 | TotalAmt |
| Program Services | $5,416,393 | ProgramServicesAmt |
| Management And General | $1,671,667 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $487,395 | TotalAmt |
| Program Services | $371,690 | ProgramServicesAmt |
| Management And General | $115,705 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $712,678 | TotalAmt |
| Program Services | $521,219 | ProgramServicesAmt |
| Management And General | $191,459 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $639,060 | TotalAmt |
| Program Services | $486,325 | ProgramServicesAmt |
| Management And General | $152,735 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $21,109 | TotalAmt |
| Program Services | $7,465 | ProgramServicesAmt |
| Management And General | $13,644 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $44,605 | TotalAmt |
| Management And General | $44,605 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,102,875 | TotalAmt |
| Program Services | $812,580 | ProgramServicesAmt |
| Management And General | $290,295 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $243,926 | TotalAmt |
| Management And General | $243,926 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $303,687 | TotalAmt |
| Program Services | $165,722 | ProgramServicesAmt |
| Management And General | $137,965 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $573,272 | TotalAmt |
| Program Services | $311,452 | ProgramServicesAmt |
| Management And General | $261,820 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $573,576 | TotalAmt |
| Program Services | $427,632 | ProgramServicesAmt |
| Management And General | $145,944 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $473,452 | TotalAmt |
| Program Services | $406,443 | ProgramServicesAmt |
| Management And General | $67,009 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $463,937 | TotalAmt |
| Program Services | $292,306 | ProgramServicesAmt |
| Management And General | $171,631 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,922 | TotalAmt |
| Program Services | $23,054 | ProgramServicesAmt |
| Management And General | $7,868 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $90,062 | TotalAmt |
| Management And General | $90,062 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| DUES AND SUBSCRIPTIONS | $31,584 | $16,672 | $14,912 |
| MISCELLANEOUS | $8,317 | $61 | $8,256 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $17,552,600 | TotalAmt |
| Program Services | $13,428,896 | ProgramServicesAmt |
| Management And General | $4,123,704 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,891,967 | BOYAmt |
| EOY | $8,304,830 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,019,135 | BOYAmt |
| EOY | $2,281,093 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $385,302 | BOYAmt |
| EOY | $1,581,850 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $518,992 | BOYAmt |
| EOY | $993,569 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $102,576 | BOYAmt |
| EOY | $42,677 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $462,785 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $378,951 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $76,758 | BOYAmt |
| EOY | $83,834 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,402,760 | BOYAmt |
| EOY | $3,143,650 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $109,973 | BOYAmt |
| EOY | $226,347 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,507,463 | BOYAmt |
| EOY | $16,657,850 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $900,763 | BOYAmt |
| EOY | $1,209,284 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,404,571 | BOYAmt |
| EOY | $6,353,841 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $55,040 | BOYAmt |
| EOY | $67,613 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,360,374 | BOYAmt |
| EOY | $7,630,738 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,147,089 | BOYAmt |
| EOY | $9,027,112 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,147,089 | BOYAmt |
| EOY | $9,027,112 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,507,463 | BOYAmt |
| EOY | $16,657,850 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $911,714 | ReconcilationRevenueExpnssAmt |
| Prior Period Adjustments | -$31,691 | PriorPeriodAdjustmentsAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $10,197,464 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,085,049 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,019,550 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,698,823 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $12,978,641 | CurrentTaxYearAmt |
| Total | $53,979,527 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $10,197,464 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,085,049 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,019,550 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,698,823 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $12,978,641 | CurrentTaxYearAmt |
| Total | $53,979,527 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $21,605,657 | SubstantialContributorsTotAmt |
| Public Support Total170 | $32,373,870 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $80,580 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $48,471 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $83,667 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $215,046 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $156,753 | CurrentTaxYearAmt |
| Total | $584,517 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $54,564,044 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $26,978,211 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.59330 | PublicSupportCY170Pct |
| Public Support PY170 | 0.51470 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $17,552,600 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $17,552,600 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $909,814 | CurrentYearMinus3Amt |
| Current Year Minus2 | $875,586 | CurrentYearMinus2Amt |
| Current Year Minus1 | $918,648 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $3,704,048 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $5,556,072 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $61,348 | CurrentYearMinus3Amt |
| Current Year Minus2 | $60,816 | CurrentYearMinus2Amt |
| Total | $122,164 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $227,454 | CurrentYearMinus3Amt |
| Current Year Minus2 | $218,897 | CurrentYearMinus2Amt |
| Current Year Minus1 | $229,662 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $926,013 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,389,020 | GrassrootsCeilingAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-A, LINE 1B | FormAndLineReferenceDesc |
| Explanation | C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. C-PATH DOES EXPEND A MINOR AMOUNT OF TIME AND MONEY TO EDUCATE LEGISLATORS AND THEIR STAFF IN THE AREA OF DRUG DEVELOPMENT. | ExplanationTxt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $42,014 | OtherCostOrOtherBasisAmt |
| Depreciation | $42,014 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $161,531 | OtherCostOrOtherBasisAmt |
| Depreciation | $145,992 | DepreciationAmt |
| Book Value | $15,539 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $259,240 | OtherCostOrOtherBasisAmt |
| Depreciation | $190,945 | DepreciationAmt |
| Book Value | $68,295 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $83,834 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | DEFERRED RENT | Desc |
| Amt | $67,613 | Amt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $67,613 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(1). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | 0 | 0 | GRANTS TO RECIPIENTS LOCATED IN REGION | CLINICAL RESEARCH | $198,459 |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | 0 | 0 | INVESTMENT | $111,924 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $310,383 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $310,383 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (7 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | SUBAWARD | $69,712 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | SUBAWARD | $10,785 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | UL HYPERCOMPUTING WORK | $28,001 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | REGULATORY FEES | $19,801 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | CLINICAL RESEARCH | $15,035 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | T&M WORK | $43,752 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | CLINICAL RESEARCH | $11,373 | WIRE TRANSFER |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 7 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (1) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. |
| PART III ACCOUNTING METHOD: |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (9 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| BAYLOR RESEARCH INSTITUTE | |||||||
| 2001 BRYAN ST SUITE 2200 | DALLAS | TX | 75201 | 751921898 | 501(C)(3) | $995,538 | DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | |||||||
| 1855 FOLSOM STREET BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | STATE OF CALIFORNIA | $502,984 | TUBERCULOSIS RESEARCH |
| UNIVERSITY OF FLORIDA | |||||||
| PO BOX 113001 | GAINSVILLE | FL | 32611 | 596002052 | STATE OF FLORIDA | $50,000 | DUCHENNE'S MUSCULAR DYSTROPHY MODEL BASED SIMULATION TOOL |
| THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | |||||||
| 445 N FIFTH STREET SUITE 600 | PHOENIX | AZ | 85004 | 753065445 | 501(C)(3) | $35,000 | ANTI MICROBIAL RESISTANCE DATA PROJECT |
| NORTHWESTERN UNIVERSITY | |||||||
| 625 N MICHIGAN AVENUE STE 2700 | CHICAGO | IL | 60611 | 362167817 | 501(C)(3) | $162,655 | CLINICAL OUTCOME RESEARCH |
| NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD) | |||||||
| DEPT 5430 PO BOX 4110 | WOBURN | MA | 01888 | 133223946 | 501(C)(3) | $712,409 | RARE DISEASE EFFORTS |
| VERASCI INC NCT HOLDINGS INC | |||||||
| 6820 CREEK WOOD DRIVE SUITE 101 | CHAPEL HILL | NC | 27514 | 202104807 | $20,680 | PRO CONSORTIUM PROJECT | |
| UNIVERSITY OF COLORADO BARBARA DAVIS CENTER | |||||||
| 1775 AURORA CT B-140 | AURORA | CO | 80045 | 841231021 | STATE OF COLORADO | $10,200 | T1D CONSORTIUM RESEARCH |
| UNIVERSITY OF ROCHESTER | |||||||
| 265 CRITTENDEN BLVD | ROCHESTER | NY | 14642 | 160743209 | STATE OF NEW YORK | $10,000 | CPP DATA CONTRIBUTION |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 8 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (13 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DR MARTHA A BRUMFIELD | ||||||||||||||
| FORMER PRESIDENT & CEO | $236,390 | $0 | $0 | $0 | $0 | $0 | $17,167 | $0 | $6,884 | $0 | $260,441 | $0 | $0 | $0 |
| DR JOSEPH SCHEEREN | ||||||||||||||
| PRESIDENT & CHIEF EXECUTIVE OFFICER | $242,633 | $0 | $0 | $0 | $0 | $0 | $16,038 | $0 | $1,062 | $0 | $259,733 | $0 | $0 | $0 |
| DR LYNN HUDSON | ||||||||||||||
| CHIEF SCIENCE OFFICER | $210,012 | $0 | $0 | $0 | $0 | $0 | $15,919 | $0 | $1,772 | $0 | $227,703 | $0 | $0 | $0 |
| DR JOHN MICHEL SAUER | ||||||||||||||
| PROGRAM OFFICER | $195,991 | $0 | $0 | $0 | $0 | $0 | $16,259 | $0 | $15,342 | $0 | $227,592 | $0 | $0 | $0 |
| DR STEPHEN COONS | ||||||||||||||
| PROGRAM OFFICER | $187,345 | $0 | $0 | $0 | $0 | $0 | $15,212 | $0 | $11,699 | $0 | $214,256 | $0 | $0 | $0 |
| DR DIANE STEPHENSON | ||||||||||||||
| EXECUTIVE DIRECTOR | $175,666 | $0 | $0 | $0 | $0 | $0 | $14,310 | $0 | $11,474 | $0 | $201,450 | $0 | $0 | $0 |
| DR KLAUS ROMERO | ||||||||||||||
| CHIEF SCIENCE OFFICER | $182,952 | $0 | $0 | $0 | $0 | $0 | $5,533 | $0 | $11,621 | $0 | $200,106 | $0 | $0 | $0 |
| DR INISH O'DOHERTY | ||||||||||||||
| EXECUTIVE DIRECTOR | $181,018 | $0 | $0 | $0 | $0 | $0 | $14,438 | $0 | $1,768 | $0 | $197,224 | $0 | $0 | $0 |
| MS SONYA EREMENCO | ||||||||||||||
| ASSOCIATE DIRECTOR | $160,608 | $0 | $0 | $0 | $0 | $0 | $13,411 | $0 | $11,259 | $0 | $185,278 | $0 | $0 | $0 |
| DR RICHARD LIWSKI | ||||||||||||||
| CHIEF TECHNOLOGY OFFICER | $163,994 | $0 | $0 | $0 | $0 | $0 | $11,221 | $0 | $6,763 | $0 | $181,978 | $0 | $0 | $0 |
| DR ARIANA MULLIN | ||||||||||||||
| EXECUTIVE DIRECTOR | $154,963 | $0 | $0 | $0 | $0 | $0 | $12,392 | $0 | $6,730 | $0 | $174,085 | $0 | $0 | $0 |
| DR MARCO SHITO | ||||||||||||||
| SCIENTIFIC DIRECTOR | $138,031 | $0 | $0 | $0 | $0 | $0 | $10,566 | $0 | $11,094 | $0 | $159,691 | $0 | $0 | $0 |
| MR STEVEN BROADBENT | ||||||||||||||
| FORMER COO & TREASURER | $123,553 | $0 | $0 | $0 | $0 | $0 | $10,129 | $0 | $7,950 | $0 | $141,632 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 7 | FormAndLineReferenceDesc |
| Explanation | VARIABLE PAY MAY BE ISSUED BASED UPON PERFORMANCE AT THE DISCRETION OF THE DEPARTMENT HEAD. | ExplanationTxt |
Schedule L IRS990ScheduleL
Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp
Name Of Interested NameOfInterested
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | AMY PORTER | PersonNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Relationship Description | SPOUSE OF JOHN-MICHAEL SAUER, KEY EMPLOYEE | RelationshipDescriptionTxt |
| Transaction | $135,850 | TransactionAmt |
| Transaction | CONSULTING SERVICES - SCIENTIFIC/TECHNICAL WRITING | TransactionDesc |
| Sharing Of Revenues | 0 | SharingOfRevenuesInd |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO ADVANCING MULTIPLE ASPECTS OF THE FDA'S CRITICAL PATH INITIATIVE (CPI), BY ESTABLISHING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA), THE REGULATED MEDICAL PRODUCT INDUSTRY, ACADEMIA, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT ADVANCE MEDICAL INNOVATION THROUGH THE DEVELOPMENT OF TOOLS AND METHODS BASED UPON SOUND, CONSENSUS-BASED SCIENCE. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) CONSORTIUM DEVELOPS TOOLS AND NOVEL METHODOLOGIES TO ACCELERATE PROGRESS IN THE DEVELOPMENT OF PREVENTION AND TREATMENT STRATEGIES FOR ALZHEIMER'S DISEASE (AD). THIS YEAR'S ACCOMPLISHMENTS INCLUDE: (1) SPEAR-HEADING AN INDUSTRY DATA-SHARING INITIATIVE TO EXPAND THE ACQUISITION OF CONTEMPORARY PATIENT-LEVEL CLINICAL TRIAL DATA THAT WILL BE INCORPORATED INTO A COMPREHENSIVE DISEASE PROGRESSION MODEL ACROSS THE AD CONTINUUM. (2) EXPANDING THE AD CLINICAL TRIAL DATA REPOSITORY TO 41 STUDIES WITH 20,549 INDIVIDUAL ANONYMIZED PATIENT RECORDS. IT HAS BEEN UTILIZED BY 456 APPROVED APPLICANTS FROM AROUND THE GLOBE, COVERING OVER 150 DISTINCT ORGANIZATIONS FROM PHARMACEUTICAL INDUSTRY, GOVERNMENT AGENCIES, NONPROFIT ORGANIZATIONS, ACADEMIA, AND INDEPENDENT RESEARCHERS, FROM MORE THAN 40 DIFFERENT COUNTRIES. (3) CONVENING A QUANTITATIVE MODELING WORKING GROUP TO SUPPORT THE GENERATION OF ACTIONABLE AD DRUG DEVELOPMENT TOOLS. THE CRITICAL PATH FOR PARKINSON'S CONSORTIUM'S (CPP) GOALS ARE TO DEVELOP QUANTITATIVE MODEL-BASED TOOLS TO ACCELERATE THE TREATMENT OF PARKINSON'S DISEASE (PD), ESPECIALLY FOR THOSE INDIVIDUALS EXPERIENCING THE FIRST CLINICAL SIGNS OF MOTOR SYMPTOM ONSET. ACCOMPLISHMENTS THIS YEAR INCLUDE:(1) LAUNCHED STAGE 2 OF THE DIGITAL DRUG DEVELOPMENT TOOLS (3DT) PROJECT WITH A GOAL TO ACQUIRE DATA FROM DIGITAL DEVICES TO BETTER UNDERSTAND HOW TO MANAGE, DISTRIBUTE, STANDARDIZE, AND APPLY THESE DATA TO OPTIMIZE PD CLINICAL TRIALS. (2) EXPANDED THE PD INTEGRATED DATABASE TO OVER 12,000 SUBJECTS FROM FIVE OBSERVATIONAL STUDIES AND 13 CLINICAL TRIALS IN PD. THE MISSION OF THE CRITICAL PATH TO TB DRUG REGIMENS (CPTR) INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF NOVEL TB DRUG REGIMENS THAT ARE SAFER, SHORTER, AND MORE EFFICACIOUS THAN THE CURRENT STANDARD OF CARE. THEIR MISSION EXPANDED TO ACCELERATE THE DEVELOPMENT OF A CLINICALLY USEFUL IN VITRO RAPID DRUG SUSCEPTIBILITY ASSAY TO SUPPORT TB REGIMEN DEVELOPMENT AND DEPLOYMENT. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) ENRICHED THE TB PLATFORM FOR AGGREGATION OF CLINICAL TRIALS (TB-PACTS), BY INCORPORATING 17 CLINICAL TRIAL DATASETS; (2) SUBMITTED DOCUMENTATION PACKAGE FOR A PRE-SUBMISSION MEETING WITH FDA CDRH TO UPDATE THE AGENCY ON THE RELATIONAL SEQUENCING FOR TB (RESEQTB) DATABASE PROGRESS, GAIN A LETTER OF SUPPORT FROM CDRH, AND DEFINE A REGULATORY PATH FORWARD; AND (3) COMPLETED THE ADAPTIVE TRIAL DESIGN PROJECT AND FINALIZED A QUANTITATIVE PLATFORM TO DETERMINE THE UTILITY OF ADAPTIVE TRIAL DESIGNS AS NOVEL CLINICAL DEVELOPMENT STRATEGIES. THE CRITICAL PATH FOR SICKLE CELL DISEASE (CP-SCD) CONSORTIUM WAS LAUNCHED IN APRIL OF 2020. IT IS A COLLABORATION SET UP TO DEVELOP COMMUNITY CONSENSUS ON HOW TO OPTIMIZE AND ACCELERATE DRUG DEVELOPMENT FOR THIS RARE DISEASE. THE MISSION OF THE CP-SCD IS TO SUPPORT COLLABORATIVE DEVELOPMENT AND REGULATORY ENDORSEMENT OF NOVEL MEDICAL PRODUCT DEVELOPMENT TOOLS. THESE TOOLS WILL HELP TO OPTIMIZE AND DE-RISK CLINICAL TRIALS TO INCREASE THE EFFICIENCY IN DEVELOPING AND DELIVERING SAFE, EFFECTIVE TREATMENTS FOR PEOPLE LIVING WITH SICKLE CELL DISEASE. THE CURE DRUG REPURPOSING COLLABORATORY (CDRC) IS A PUBLIC-PRIVATE PARTNERSHIP INITIATED IN JUNE OF 2020 BY C-PATH AND THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN PARTNERSHIP WITH THE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS), PART OF THE NATIONAL INSTITUTES OF HEALTH (NIH). CDRC, IN PARTNERSHIP WITH THE FDA-NCATS CURE ID* PLATFORM, IS A DEDICATED INITIATIVE DESIGNED TO CAPTURE REAL-WORLD CLINICAL OUTCOME DATA TO ADVANCE DRUG REPURPOSING AND INFORM FUTURE CLINICAL TRIALS FOR DISEASES OF HIGH UNMET MEDICAL NEED. THE DATA COLLABORATION CENTER (DCC) IS A PROGRAM WITHIN C-PATH TO ENABLE MULTIPLE ORGANIZATIONS TO WORK TOGETHER IN A NEUTRAL SETTING AND SHARE CLINICAL DATA IN ORDER TO OPTIMIZE ITS VALUE IN CREATING NEW INSIGHTS AND TOOLS THAT ACCELERATE DRUG DEVELOPMENT IN AREAS WITH UNMET MEDICAL NEEDS. THE DCC SUPPORTS DATA SHARING PROJECTS ALIGNED WITH SPECIFIC C-PATH CONSORTIA AS WELL AS DATA SHARING INITIATIVES THAT ARE INDEPENDENT OF C-PATH CONSORTIA. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) LAUNCHED THE RARE DISEASE CURES ACCELERATOR - DATA AND ANALYTICS PLATFORM (RDCA-DAP) AND DEVELOPMENT OF PROTOTYPE DATA INTERROGATOR FOR THE RDCA-DAP; (2) COMPLETED THE ALZHEIMER'S DISEASE DATA INTEROPERABILITY PILOT PROJECT TO VALIDATE THE AD WORKBENCH PROOF OF CONCEPT AND JUSTIFY PROCEEDING TO THE SCALE-UP PHASE; (3) RECEIVED ADDITIONAL FUNDING FROM NIH TO PROCESS ISOLATES FOR THE RESEQTB INITIATIVE; AND (4) EXPANDED TB-PACTS 2.0 TO INCLUDE ADDITIONAL TB STUDIES. THE DUCHENNE REGULATORY SCIENCE CONSORTIUM'S (D-RSC) GOAL IS TO SUPPORT COLLABORATIVE RESEARCH AND REGULATORY QUALIFICATION OF NEW DRUG DEVELOPMENT TOOLS FOR DUCHENNE MUSCULAR DYSTROPHY (DMD), TO ENABLE THE EARLIEST POSSIBLE PATIENT ACCESS TO NEW TREATMENTS. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) EXPANDED THE D-RSC DATABASE TO 16 DATASETS, REPRESENTING NEARLY 5000 PEOPLE WITH DMD; AND (2) SUBMITTED A CLINICAL TRIAL SIMULATION TOOL LETTER OF INTENT AND MODELING PLAN TO FDA AND EMA AND INITIATED WORK ON CLINICAL TRIAL SIMULATION PLATFORM. THE GOAL OF THE ELECTRONIC PATIENT-REPORTED OUTCOME CONSORTIUM (EPROC) IS TO ADVANCE THE SCIENCE OF CLINICAL TRIAL ENDPOINT ASSESSMENT BY COLLABORATIVELY SUPPORTING AND CONDUCTING RESEARCH, DESIGNING AND DELIVERING EDUCATIONAL OPPORTUNITIES, AND DEVELOPING AND DISSEMINATING BEST PRACTICE RECOMMENDATIONS FOR ELECTRONIC COLLECTION OF CLINICAL OUTCOME DATA. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) LAUNCHED THE ECOA: GETTING BETTER TOGETHER INITIATIVE TO ADDRESS CHALLENGES WITH THE IMPLEMENTATION OF ELECTRONIC COAS (ECOAS) IN CLINICAL TRIALS; (2) PARTICIPATED IN THE PREPARATION OF AN FDA DDT RESEARCH GRANT APPLICATION TITLED PRELIMINARY RESEARCH TO SUPPORT QUALIFICATION OF AN ACTIVITY MONITOR-BASED ENDPOINT MEASURE TO EVALUATE PHYSICAL ACTIVITY IN PERSONS WITH CHRONIC HEART FAILURE FOR DDTCOA000114; (3) LAUNCHED THE EPRO CONSORTIUM'S CHINA SUBCOMMITTEE; AND (4) IN COLLABORATION WITH THE PROC, DEVELOPED THE PRESENTATION TITLED "CORONAVIRUS DISEASE 2019 (COVID-19): RISK ASSESSMENT AND MITIGATION STRATEGIES FOR THE COLLECTION OF PATIENT-REPORTED OUTCOME (PRO) DATA THROUGH CLINICAL SITES." THE GOAL OF THE HUNTINGTON'S DISEASE REGULATORY SCIENCE CONSORTIUM (HD-RSC) IS TO BRING TOGETHER PARTICIPANTS FROM ACROSS THE GLOBAL HUNTINGTON'S DISEASE (HD) COMMUNITY WITH THE GOAL TO CREATE AND ADVANCE DRUG DEVELOPMENT TOOLS FOR REGULATORY ENDORSEMENT AND ACCELERATE THE OVERALL DEVELOPMENT OF NOVEL THERAPEUTICS FOR HD. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) CONTRIBUTED COMMENTS TO FDA DRAFT GUIDANCE ON THE USE OF NATURAL HISTORY STUDIES IN DRUG DEVELOPMENT FOR RARE DISEASES; (2) EXPANDED CONSORTIUM MEMBERSHIP THROUGH AGREEMENTS WITH NEW INDUSTRY AND NON-PROFIT MEMBERS; (3) SUBMITTED MANUSCRIPT ON STANDARDIZED DATA STRUCTURES IN RARE DISEASES TO CLINICAL AND TRANSLATIONAL SCIENCE; (4) FINALIZED TERMS AND CONDITIONS FOR USERS TO GAIN ACCESS TO THE HD AGGREGATED DATABASE; AND (5) EXPANDED HD DATABASE, CURRENTLY REPRESENTING 16,500 PATIENTS. AT THE REQUEST OF THE FDA, C-PATH FORMED AN INTERNATIONAL NEONATAL CONSORTIUM (INC). THE PURPOSE OF THE CONSORTIUM IS TO ACCELERATE THE DEVELOPMENT OF SAFE AND EFFECTIVE THERAPIES FOR NEONATES. INC ENGAGES THE GLOBAL NEONATAL COMMUNITY - FAMILIES, NEONATAL NURSES, ACADEMIC SCIENTISTS, REGULATORS, PHARMACEUTICAL INVESTIGATORS, ADVOCACY ORGANIZATIONS, AND FUNDERS - TO FOCUS ON THE NEEDS OF THE NEONATE. ACCOMPLISHMENTS THIS YEAR INCLUDE DEVELOPING RECOMMENDED NEONATAL BLOOD PRESSURE MEASUREMENT METHODS BASED ON A SYSTEMATIC LITERATURE REVIEW AND ANALYSIS, INCLUDING ORIGINAL ARTWORK WITH A DIAGRAM ILLUSTRATING PROPER BLOOD PRESSURE CUFF PLACEMENT. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENTS CONSORTIUM (MSOAC) HAS A GOAL TO OBTAIN REGULATORY QUALIFICATION OF AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT AS A PRIMARY OR SECONDARY ENDPOINT IN CLINICAL TRIALS OF MULTIPLE SCLEROSIS (MS) THERAPIES. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECEIVED FINAL POSITIVE QUALIFICATION OPINION ADOPTED BY THE CHMP/EMA; AND (2) RECEIVED POSITIVE DETERMINATION LETTER FROM FDA COA QUALIFICATION PROGRAM ACCEPTING THE QUALIFICATION PLAN FOR USE OF SYMBOL DIGIT MODALITIES TEST TO ASSESS COGNITION IN TRIALS OF MS THERAPIES. THE POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM (PKD-OC) HAS DEVELOPED AND OBTAINED REGULATORY QUALIFICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND THE EUROPEAN MEDICINES AGENCY (EMA) OF TOTAL KIDNEY VOLUME (TKV) AS A PROGNOSTIC BIOMARKER FOR USE IN CLINICAL TRIALS FOR NEW THERAPIES FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). THE CONSORTIUM CONTINUES TO EXPLORE ALTERNATE SOLUTIONS TO ACCELERATE THE DEVELOPMENT OF NOVEL MEDICAL PRODUCTS FOR INDIVIDUALS LIVING WITH PKD, WHICH INCLUDE QUANTITATIVE DISEASE PROGRESSION MODELS, CLINICAL ENDPOINTS, INCLUDING A COMPOSITE ENDPOINT, INNOVATIVE CLINICAL TRIAL DESIGNS, AND REGULATORY PATHWAYS TO HELP EXPEDITE NEW THERAPIES IN PKD. THE FDA HAS COMMUNICATED THAT TKV IS A "REASONABLY LIKELY SURROGATE," WHICH MAKES IT ELIGIBLE FOR AN ACCELERATED APPROVAL PROCESS AT THE FDA. A NEW TKV MODELING PROPOSAL HAS BEEN INITIATED THIS YEAR; THIS EFFORT WILL RESULT IN THE DEVELOPMENT OF TOOLS TO OPTIMIZE CLINICAL TRIAL DESIGN FOR PKD THERAPIES. THE PATIENT-REPORTED OUTCOME CONSORTIUM (PROC) HAS A GOAL TO ESTABLISH AND MAINTAIN A COLLABORATIVE FRAMEWORK WITH APPROPRIATE STAKEHOLDERS FOR THE QUALIFICATION OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS AND OTHER CLINICAL OUTCOME ASSESSMENT (COA) TOOLS THAT WILL BE MADE AVAILABLE FOR USE IN CLINICAL TRIALS WHERE COA-BASED ENDPOINTS ARE USED TO SUPPORT PRODUCT LABELING CLAIMS. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECEIVED ADVICE LETTER FROM FDA IN RESPONSE TO THE INITIAL BRIEFING PACKAGE SUBMITTED BY THE MULTIPLE SCLEROSIS WORKING GROUP FOR QUALIFICATION OF THE PROMIS SHORT FORM V1.0-FATIGUE-MULTIPLE SCLEROSIS 8A (PROMIS FATIGUEMS-8A); (2) THE SMALL CELL LUNG CANCER WORKING GROUP SUBMITTED A LETTER OF INTENT (LOI) TO FDA FOR A NEW MEASURE DERIVED FROM THE NSCLC-SAQ V1.0 AND RECEIVED A REVIEWABILITY MEMORANDUM FROM FDA; (3) RECEIVED THE OK FROM FDA TO MOVE FORWARD WITH DEVELOPMENT OF A QUALIFICATION PLAN FOR THE SYMPTOMS OF MAJOR DEPRESSIVE DISORDER DIARY (SMDDD); AND (4) IN COLLABORATION WITH THE EPROC, DEVELOPED THE PRESENTATION TITLED "CORONAVIRUS DISEASE 2019 (COVID-19): RISK ASSESSMENT AND MITIGATION STRATEGIES FOR THE COLLECTION OF PATIENT-REPORTED OUTCOME (PRO) DATA THROUGH CLINICAL SITES." THE PREDICTIVE SAFETY TESTING CONSORTIUM (PSTC) HAS A GOAL TO BRING TOGETHER PHARMACEUTICAL COMPANIES TO SHARE AND VALIDATE INNOVATIVE SAFETY TESTING METHODS UNDER ADVISEMENT OF THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), EUROPEAN MEDICINES AGENCY (EMA), AND JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA). CURRENTLY PSTC IS FOCUSED ON DEVELOPING AND OBTAINING REGULATORY QUALIFICATION OF IMPROVED CLINICAL SAFETY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. THIS YEAR THE CONSORTIUM'S ACCOMPLISHMENTS INCLUDE: (1) INITIATED THE PREDICTOX PROJECT, FOCUSED ON THE DEVELOPMENT OF QUANTITATIVE TOOLS TO BETTER PREDICT CLINICAL SAFETY FOR PRECLINICAL DATA, IN COOPERATION WITH THE ICAHN SCHOOL OF MEDICINE AT MT. SINAI AND FDA; (2) A LETTER OF INTENT FOR QUALIFICATION OF DRUG-INDUCED MUSCLE INJURY BIOMARKERS ADVANCED TO THE STAGE TWO REVIEW AT FDA; AND (3) THE QUALIFICATION PLAN FOR GLUTAMATE DEHYDROGENASE (GLDH) AS A BIOMARKER TO DETECT DRUG-INDUCED LIVER INJURY ADVANCED TO THE STAGE TWO REVIEW AT FDA. THE WORK OF THE QUANTITATIVE MEDICINE PROGRAM (QUANTMED) FOCUSES ON THE DEVELOPMENT AND INNOVATION OF QUANTITATIVE SOLUTIONS FOR MEDICAL PRODUCT DEVELOPMENT AND CLINICAL NEEDS, WITH THE AIM OF IMPROVING POPULATION AND INDIVIDUAL HEALTH BY TRANSFORMING DRUG DEVELOPMENT THROUGH METHODOLOGICAL INNOVATION. THE PROGRAM GOAL IS TO LEVERAGE KNOWLEDGE FROM A NETWORK OF EXPERTS IN INDUSTRY, ACADEMIA, NON-PROFIT AND REGULATORY SCIENCES COMBINED WITH DATA ACQUIRED FROM MULTIPLE SOURCES TO DEVELOP QUANTITATIVE METHODOLOGIES IN PHARMACOMETRICS, STATISTICS, SYSTEMS PHARMACOLOGY, ARTIFICIAL INTELLIGENCE AND DIGITAL DATA ANALYTICS. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECEIVED FUNDING FROM FDA TO DEVELOP TRAINING MODULES FOR MODEL-INFORMED DRUG DEVELOPMENT (MIDD) FOR REGULATORS; (2) PROVIDED CRITICAL SUPPORT TO D-RSC THE SAWP MEETING WITH EMA FOR THE DUCHENNE CLINICAL TRIAL SIMULATION TOOL; AND (3) REPRESENTED RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) AT FDA RARE DISEASE DAY, LEADING A PANEL ON RARE DISEASE PROGRESSION MODELING; (4) ADVANCED TO CRITICAL DEMONSTRATION PROJECTS WITHIN RDCA-DAP, FOR THE GENERATION OF QUANTITATIVE SOLUTIONS TO ACCELERATE DRUG DEVELOPMENT IN ORPHAN INDICATIONS; (5) SUPPORTED CPP'S SUCCESSFUL 3DT PROJECT; (6) SUPPORTED THE T1D CONSORTIUM IN THE SUCCESSFUL LAUNCH OF THE TRIAL OUTCOME MARKERS INITIATIVE (TOMI); AND (7) SUPPORTED THE TTC IN THE SUBMISSION OF THE LETTER OF INTENT TO FDA BIOMARKER QUALIFICATION PROGRAM TO SEEK FORMAL QUALIFICATION OF A REASONABLY LIKELY SURROGATE ENDPOINT (RLSE) FOR USE IN TRANSPLANTATION CLINICAL TRIALS. THE RARE DISEASE CURES ACCELERATOR-DATA AND ANALYTICS PLATFORM (RDCA-DAP) IS AN FDA-FUNDED INITIATIVE THAT PROVIDES A CENTRALIZED AND STANDARDIZED INFRASTRUCTURE TO SUPPORT AND ACCELERATE RARE DISEASE CHARACTERIZATION, WITH THE GOAL OF ACCELERATING THERAPY DEVELOPMENT ACROSS RARE DISEASES. THIS PLATFORM IS MADE POSSIBLE THROUGH A COLLABORATIVE GRANT FROM THE FDA AND IN PARTNERSHIP WITH THE NATIONAL ORGANIZATION FOR RARE DISORDERS (NORD). RDCA-DAP PROMOTES THE SHARING OF EXISTING PATIENT-LEVEL DATA AND ENCOURAGES THE STANDARDIZATION OF NEW DATA COLLECTION. BY INTEGRATING SUCH DATA IN A REGULATORY-GRADE FORMAT SUITABLE FOR ANALYTICS, RDCA- DAP ACCELERATES THE UNDERSTANDING OF DISEASE PROGRESSION (INCLUDING SOURCES OF VARIABILITY TO OPTIMIZE THE CHARACTERIZATION OF SUBPOPULATIONS), CLINICAL OUTCOME MEASURES AND BIOMARKERS, AND FACILITATES THE DEVELOPMENT OF MATHEMATICAL MODELS OF DISEASE AND INNOVATIVE CLINICAL TRIAL DESIGNS. RDCA-DAP IS POSITIONED TO GENERATE SOLUTIONS TO DRUG DEVELOPMENT BOTTLENECKS. ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) INITIATIVE LAUNCHED; (2) INTEGRATED DATA FROM ~28,000 PATIENTS INTO THE RDCA-DAP; AND (3) EXPLORED PARTNERSHIPS TO FACILITATE SHARING OF DATA AND TECHNOLOGY WITH THE COMMUNITY, OUTREACH AND COMMUNICATIONS TO 100+ GROUPS INCLUDING INDUSTRY, NIH AND PATIENT GROUPS. THE TYPE I DIABETES CONSORTIUM (T1D) IS FOCUSING ON QUALIFYING ISLET AUTOIMMUNITY ANTIBODIES AS SUSCEPTIBILITY/RISK BIOMARKERS TO BE USED IN THE DEVELOPMENT OF THERAPIES FOR THE TREATMENT, AND ULTIMATELY, THE PREVENTION, OF TYPE 1 DIABETES. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: (1) INITIATED TRIAL OUTCOME MARKERS INITIATIVE (TOMI) AND CONVENED STAKEHOLDERS IN 2020 IN RESPONSE TO T1D COMMUNITY DRUG DEVELOPMENT NEEDS; (2) RECEIVED FDA FUNDING TO BEGIN A COMPREHENSIVE ASSESSMENT TO UNDERSTAND THE RELATIONSHIPS BETWEEN CONTINUOUS GLUCOSE MONITORING MEASURES AND ESTABLISHED MEASURES OF GLYCEMIC CONTROL; AND (3) INITIATED AN ISLET AA ASSAY MODERNIZATION PROJECT. THE TRANSPLANTATION THERAPEUTICS CONSORTIUM IS WORKING TO IDENTIFY MECHANISMS AND DRUG DEVELOPMENT TOOLS TO ACCELERATE DRUG DISCOVERY FOR TRANSPLANT PATIENTS, THROUGH THE COLLABORATIVE INVOLVEMENT OF KEY STAKEHOLDERS IN THE FIELD. THE CONSORTIUM IS INITIALLY FOCUSING ON KIDNEY TRANSPLANT BUT MAY EXPAND TO OTHER SOLID ORGAN TRANSPLANTS IN THE FUTURE. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: (1) SUBMITTED LETTER OF INTENT TO FDA BIOMARKER QUALIFICATION PROGRAM TO SEEK FORMAL QUALIFICATION OF A REASONABLY LIKELY SURROGATE ENDPOINT (RLSE) FOR USE IN TRANSPLANTATION CLINICAL TRIALS; AND (2) INITIATED THE CREATION OF AN AGGREGATED PATIENT-LEVEL DATABASE USING REAL-WORLD EVIDENCE AND HISTORICAL CLINICAL TRIAL DATA. |
| FORM 990, PART VI, SECTION A, LINE 2 | PETER HUTT AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. WAIN FISHBURN AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S DIRECTOR OF FINANCE, COO, PRESIDENT/CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. |
| FORM 990, PART VI, SECTION B, LINE 12C | ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. |
| FORM 990, PART VI, SECTION B, LINE 15 | A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. PERIODICALLY, THE COMMITTEE REQUESTS A COMPENSATION ANALYSIS TO DETERMINE IF EMPLOYEE COMPENSATION HAS REMAINED WITHIN MARKET RANGE OR IF ADJUSTMENTS ARE REQUIRED. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. |
| FORM 990, PART VI, SECTION C, LINE 19 | ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. |
Schedule R IRS990ScheduleR
Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (2 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Entity TypeEntityTypeTxt | OwnershipOwnershipPct | Controlled OrganizationControlledOrganizationInd | Share Of Total IncomeShareOfTotalIncomeAmt | Share Of EOY AssetsShareOfEOYAssetsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRITICAL PATH GLOBAL LTD | |||||||||||
| 20-22 BEDFORD ROW | LONDON | UK | WC1R 4JS | FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | UK | CRITICAL PATH INSTITUTE | C | 1.00000 | Yes (1) | ||
| CRITICAL PATH INSTITUTE LTD | |||||||||||
| 33 SIR JOHN ROGERSONS QUAY | DUBLIN | EI | 2 | FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | EI | CRITICAL PATH INSTITUTE | C | 1.00000 | Yes (1) | $36,141 | $680,634 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | 0 | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | Yes (1) | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp
Other Organization Name OtherOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE LTD | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Transaction Type | D | TransactionTypeTxt |
| Involved | $111,924 | InvolvedAmt |
| Method Of Amount Determination | CASH | MethodOfAmountDeterminationTxt |